Supplementary Fig. 3 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST) | Synapse
September 16, 2024
Supplementary Fig. 3 from Anti-tumor efficacy of the novel KIT inhibitor IDRX-42 (formerly M4205) in patient- and cell line-derived xenograft models of gastrointestinal stromal tumor (GIST)
Key Points
Key points are not available for this paper at this time.
Abstract
Supplementary Fig. 3. One histologically representative picture of H&E staining per treatment group in the experiment with GIST882KIT13.